Atlas Molecular Pharma (Atlas), a biotechnology company and spin-off of CIC bioGUNE, has closed a €3 million investment round aimed at driving the clinical development of ATL-001, its oral clinical-stage therapy for the treatment of Congenital Erythropoietic Porphyria (CEP), an ultra-rare disease with no approved treatments.
The round was led by Inveready, with participation from CDTI (Invierte program), Grupo SPRI (Ezten FCR), Kereon Partners, Endometrial DIDI, and CRB Inverbio. This funding will enable the company to carry out a Phase I–II clinical trial, bringing ATL-001 closer to the market and to patients.
With this capital injection, Atlas will complete a Phase I–II trial (ATL001-PII-CEP) of its lead compound, ATL-001, with patient enrollment for Congenital Erythropoietic Porphyria in the United States scheduled to begin in February 2026.
ATL-001 has held orphan drug designation in Europe (OMP) and the United States (ODD) since 2018. In addition, in 2025 it received Fast Track Designation from the U.S. Food and Drug Administration (FDA), was included in the Rare Disease Endpoint Advancement (RDEA) Pilot Program, and was awarded a $2.5 million grant from the FDA’s Office of Orphan Products Development (OOPD) to also support the Phase II clinical development of the ATL001-PII-CEP study.
About Atlas Molecular Pharma
Atlas Molecular Pharma is a biotechnology company and a spin-off of CIC bioGUNE, headquartered at the Bizkaia Science and Technology Park, focused on the development of innovative therapies for rare and ultra-rare diseases. Its technology platform includes second-generation pharmacological chaperones, and the company operates under an open innovation model in collaboration with academic centers and industry partners. The company is led by its CEO, Dr. Susana Castel, and by its founder and Chief Scientific Officer, Dr. Oscar Millet. Atlas currently has a team of eight professionals.
